SSShivajanani Sivakumaran

Shivajanani Sivakumaran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shivajanani Sivakumaran has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients

    by Rebecca Pike, Niclas Thomas, Sarita Workman, Lyn Ambrose, David Guzman, Shivajanani Sivakumaran, Margaret Johnson, Douglas Thorburn, Mark Harber, Benny Chain, et al.

    We tested whether multi-parameter immune phenotyping before or after renal transplantation can predict the risk of rejection episodes. Blood samples collected before, and weekly for 3 months after transplantation were analyzed by multi-parameter flow-cytometry to define 52 T cell and 13 innate lymphocyte subsets in each sample, producing more than 11,000 data points that defined the immune status of the 28 patients included in this study. Principle component analysis suggested that the patients with histologically confirmed rejection episodes segregated from those without rejection. Protein death 1 (PD-1)-expressing subpopulations of regulatory and conventional T cells had the greatest influence on the principal component segregation. We constructed a statistical tool to predict rejection using a support vector machine algorithm. The algorithm correctly identified 7 out of 9 patients with rejection, and 14 out of 17 patients without rejection. The immune profile before transplantation was most accurate in determining the risk of rejection, while changes of immune parameters after transplantation were less accurate in discriminating rejection from non-rejection. The data indicate that pre-transplant immune subset analysis has the potential to identify patients at risk of developing rejection episodes, and suggests that the proportion of PD1-expressing T cell subsets may be a key indicator of rejection risk.


  • Open Access

    Depletion of CD11c+ cells in the CD11c.DTR model drives expansion of unique CD64+ Ly6C+ monocytes that are poised to release TNF‐α

    by Shivajanani Sivakumaran, Stephen Henderson, Sophie Ward, Pedro Santos E. Sousa, Teresa Manzo, Lei Zhang, Thomas Conlan, Terry K. Means, Maud D'Aveni, Olivier Hermine, et al.

    Dendritic cells (DCs) play a vital role in innate and adaptive immunities. Inducible depletion of CD11c+ DCs engineered to express a high‐affinity diphtheria toxin receptor has been a powerful tool to dissect DC function in vivo. However, despite reports showing that loss of DCs induces transient monocytosis, the monocyte population that emerges and the potential impact of monocytes on studies of DC function have not been investigated. We found that depletion of CD11c+ cells from CD11c.DTR mice induced the expansion of a variant CD64+ Ly6C+ monocyte population in the spleen and blood that was distinct from conventional monocytes. Expansion of CD64+ Ly6C+ monocytes was independent of mobilization from the BM via CCR2 but required the cytokine, G‐CSF. Indeed, this population was also expanded upon exposure to exogenous G‐CSF in the absence of DC depletion. CD64+ Ly6C+ monocytes were characterized by upregulation of innate signaling apparatus despite the absence of inflammation, and an increased capacity to produce TNF‐α following LPS stimulation. Thus, depletion of CD11c+ cells induces expansion of a unique CD64+ Ly6C+ monocyte population poised to synthesize TNF‐α. This finding will require consideration in experiments using depletion strategies to test the role of CD11c+ DCs in immunity.


  • G-CSF mobilizes CD34 + regulatory monocytes that inhibit graft-versus-host disease

    by Maud D’aVeni, Julien Rossignol, Tereza Coman, Shivajanani Sivakumaran, Stephen Henderson, Teresa Manzo, Pedro Santos e Sousa, Julie Bruneau, Guillemette Fouquet, Flora Zavala, et al.

    G-SCF–mobilized CD34 + monocytes inhibit graft-versus-host disease by the production of nitric oxide and the induction of regulatory T cells.


  • OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence

    by Sarah L. Buchan, Teresa Manzo, Barry Flutter, Anne Rogel, Noha Edwards, Lei Zhang, Shivajanani Sivakumaran, Sara Ghorashian, Ben Carpenter, Clare L. Bennett, et al.

    Exhaustion of chronically stimulated CD8+ T cells is a significant obstacle to immune control of chronic infections or tumors. Although coinhibitory checkpoint blockade with anti–programmed death ligand 1 (PD-L1) Ab can restore functions to exhausted T cell populations, recovery is often incomplete and dependent upon the pool size of a quiescent T-bethigh subset that expresses lower levels of PD-1. In a model in which unhelped, HY-specific CD8+ T cells gradually lose function following transfer to male bone marrow transplantation recipients, we have explored the effect of shifting the balance away from coinhibition and toward costimulation by combining anti–PD-L1 with agonistic Abs to the TNFR superfamily members, OX40 and CD27. Several weeks following T cell transfer, both agonistic Abs, but especially anti-CD27, demonstrated synergy with anti–PD-L1 by enhancing CD8+ T cell proliferation and effector cytokine generation. Anti-CD27 and anti–PD-L1 synergized by downregulating the expression of multiple quiescence-related genes concomitant with a reduced frequency of T-bethigh cells within the exhausted population. However, in the presence of persistent Ag, the CD8+ T cell response was not sustained and the overall size of the effector cytokine-producing pool eventually contracted to levels below that of controls. Thus, CD27-mediated costimulation can synergize with coinhibitory checkpoint blockade to switch off molecular programs for quiescence in exhausted T cell populations, but at the expense of losing precursor cells required to maintain a response.


  • Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoid

    by Annelise Soulier, Sandra M. Blois, Shivajanani Sivakumaran, Farnaz Fallah-Arani, Stephen Henderson, Barry Flutter, Elizabeth H. Rabbitt, Paul M. Stewart, Gareth G. Lavery, Clare Bennett, et al.

    Although the inhibitory effects of therapeutic glucocorticoids (GCs) on dendritic cells (DCs) are well established, the roles of endogenous GCs in DC homeostasis are less clear. A critical element regulating endogenous GC concentrations involves local conversion of inactive substrates to active 11-hydroxyglucocorticoids, a reduction reaction catalyzed within the endoplasmic reticulum by an enzyme complex containing 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and hexose-6-phosphate dehydrogenase (H6PDH). In this study, we found that this GC amplification pathway operates both constitutively and maximally in steady state murine DC populations and is unaffected by additional inflammatory stimuli. Under physiologic conditions, 11βHSD1-H6PDH increases the sensitivity of plasmacytoid DCs (pDCs) to GC-induced apoptosis and restricts the survival of this population through a cell-intrinsic mechanism. Upon CpG activation, the effects of enzyme activity are overridden, with pDCs becoming resistant to GCs and fully competent to release type I interferon. CD8α+ DCs are also highly proficient in amplifying GC levels, leading to impaired maturation following toll-like receptor–mediated signaling. Indeed, pharmacologic inhibition of 11βHSD1 synergized with CpG to enhance specific T-cell responses following vaccination targeted to CD8α+ DCs. In conclusion, amplification of endogenous GCs is a critical cell-autonomous mechanism for regulating the survival and functions of DCs in vivo. Key Points Murine dendritic cell populations are highly proficient in amplifying local glucocorticoid concentrations. This property is critical in regulating dendritic cell survival and functions in vivo.


  • Open Access

    Tumor‐primed natural killer cells from patients with multiple myeloma lyse autologous, NK‐resistant, bone marrow‐derived malignant plasma cells

    by Eirini Katodritou, Evangelos Terpos, Janet North, Panagiotis Kottaridis, Evgenia Verrou, Vasiliki Gastari, Christina Chadjiaggelidou, Shivajanani Sivakumaran, Samuel Jide‐Banwo, Maria Tsirogianni, et al.

    Natural killer (NK) cells are cytotoxic lymphocytes able to kill tumor cells and virus‐infected cells. Human‐resting NK cells can be activated by co‐culture with NK‐resistant CTV‐1a cells. These tumor‐activated cells (TaNKs) are cytotoxic to a range of NK‐resistant tumor cells in vitro. This potential, however, has not been explored in multiple myeloma (MM). In this study, we demonstrate that TaNK cells from 21 MM patients lyse a variety of myeloma targets, including primary isolates of autologous and allogeneic CD138+ myeloma cells whilst sparing CD138−ve bone marrow cells. Myeloma patients' TaNK‐induced lysis of the U266 cell line was significantly higher compared to normal controls (median‐specific lysis 79.1% vs. 69.5%) (P = 0.003). In addition, TaNKs induced substantial lysis of autologous and allogeneic CD138+ myeloma cells (median‐specific lysis 52.5% and 37.4%, respectively). The percentage of specific lysis did not correlate with important disease characteristics (ISS, age, and high‐risk molecular abnormalities) or with the disease status and antimyeloma treatment, including novel agents and dexamethasone. In conclusion, tumor‐primed NK cells are able to induce substantial lysis of myeloma targets including autologous and allogeneic CD138+ myeloma plasma cells and could be an additional therapeutic approach in MM, particularly in the era of novel agents. Am. J. Hematol., 2011.


  • Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation

    by Barry Flutter, Noha Edwards, Farnaz Fallah-Arani, Stephen Henderson, Jian-Guo Chai, Shivajanani Sivakumaran, Sara Ghorashian, Clare L. Bennett, Gordon J. Freeman, Megan Sykes, et al.

    Allogeneic blood or BM transplantation (BMT) is the most commonly applied form of adoptive cellular therapy for cancer. In this context, the ability of donor T cells to respond to recipient antigens is coopted to generate graft-versus-tumor (GVT) responses. The major reason for treatment failure is tumor recurrence, which is linked to the eventual loss of functional, host-specific CTLs. In this study, we have explored the role of recipient antigen expression by nonhematopoietic cells in the failure to sustain effective CTL immunity. Using clinically relevant models, we found that nonhematopoietic antigen severely disrupts the formation of donor CD8+ T cell memory at 2 distinct levels that operate in the early and late phases of the response. First, initial and direct encounters between donor CD8+ T cells and nonhematopoietic cells blocked the programming of memory precursors essential for establishing recall immunity. Second, surviving CD8+ T cells became functionally exhausted with heightened expression of the coinhibitory receptor programmed death-1 (PD-1). These 2 factors acted together to induce even more profound failure in long-term immunosurveillance. Crucially, the functions of exhausted CD8+ T cells could be partially restored by late in vivo blockade of the interaction between PD-1 and its ligand, PD-L1, without induction of graft-versus-host disease, suggestive of a potential clinical strategy to prevent or treat relapse following allogeneic BMT.